Methyl 2-(3-acetyl-7-propoxyindolizin-1-yl)-3-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyridine-6-carboxylate
C28H33N5O5 — CID 155512071
Data last refreshed: (MolForge compound catalog, from PubChem)
About Methyl 2-(3-acetyl-7-propoxyindolizin-1-yl)-3-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyridine-6-carboxylate
Methyl 2-(3-acetyl-7-propoxyindolizin-1-yl)-3-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyridine-6-carboxylate (PubChem CID 155512071) has the molecular formula C28H33N5O5 and a molecular weight of 519.60 g/mol. Its IUPAC name is methyl 2-(3-acetyl-7-propoxyindolizin-1-yl)-3-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyridine-6-carboxylate.
Molecular Properties
| Compound Name | Methyl 2-(3-acetyl-7-propoxyindolizin-1-yl)-3-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyridine-6-carboxylate |
|---|---|
| PubChem CID | 155512071 |
| Molecular Formula | C28H33N5O5 |
| Molecular Weight | 519.60 g/mol |
| Exact Mass | 519.25 |
| IUPAC Name | methyl 2-(3-acetyl-7-propoxyindolizin-1-yl)-3-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyridine-6-carboxylate |
| SMILES | CCCOc1ccn2c(C(C)=O)cc(-c3nc4ccc(C(=O)OC)cn4c3NCCN3CCOCC3)c2c1 |
| InChI | InChI=1S/C28H33N5O5/c1-4-13-38-21-7-9-32-23(19(2)34)17-22(24(32)16-21)26-27(29-8-10-31-11-14-37-15-12-31)33-18-20(28(35)36-3)5-6-25(33)30-26/h5-7,9,16-18,29H,4,8,10-15H2,1-3H3 |
| InChIKey | HNWYFKXIEKVTCZ-UHFFFAOYSA-N |
| XLogP | 3.78 |
| TPSA | 98.81 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 38 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 519.60 |
| LogP ≤ 5 | 3.78 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155512071 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.